Pharmaceutical & Life Sciences
Complete drug lifecycle analytics from clinical trials to FDA approval to prescribing patterns to adverse events to enforcement recalls. Replace six-figure data contracts with a from $199/month subscription.
How it works
This is a real report generated from live adverse-event data. Ask Medistill to compare any drugs , it pulls adverse events, death reports, serious outcomes, and key safety signals across the entire class.
Query
“Compare the complete adverse event profiles of the top 5 GLP-1 drugs , semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide. Show total reports, serious outcome rates, top 10 reactions for each, death counts, and which drug has the cleanest safety profile.”
FDA adverse-event database · All-time reports · Primary suspect role unless noted · Source: Medistill
Total adverse-event reports, all roles
Safety profile scorecard (lower = better)
Semaglutide
Deaths per 1k reports
6.3
Serious rate %
6.4%
Tirzepatide
Deaths per 1k reports
3.6
Serious rate %
2.4%
lowest rates
Liraglutide
Deaths per 1k reports
13.6
Serious rate %
12.3%
Dulaglutide
Deaths per 1k reports
8.8
Serious rate %
5.2%
Exenatide
Deaths per 1k reports
12.8
Serious rate %
5.7%
Key safety signals, per-drug breakdown
| Signal | Semaglutide | Tirzepatide | Liraglutide | Dulaglutide | Exenatide |
|---|---|---|---|---|---|
| Pancreatitis (all) | 2,708 | 3,617 | 2,484 | 2,269 | 1,004 |
| Acute kidney injury | 1,272 | 1,099 | 1,145 | 911 | 690 |
| Ileus | 1,521 | 1,328 | 106 | 519 | 20 |
| Suicidal ideation | 867 | 731 | 204 | 130 | 79 |
| Diabetic ketoacidosis | 647 | 374 | 583 | 530 | 191 |
| Pulmonary embolism | 324 | 420 | 382 | 115 | 94 |
| Thyroid cancer | 145 | 138 | 115 | 116 | 157 |
| Cardiac arrest | 258 | 149 | 166 | 98 | 39 |
| Acute MI | 125 | 46 | 91 | 60 | 28 |
| Death reports | 558 | 465 | 535 | 810 | 511 |
Per-drug summary cards
Semaglutide
Tirzepatide
Liraglutide
Dulaglutide
Exenatide
Analysis
Total report volumes, tirzepatide dominates with 130,176 reports despite being the newest drug, largely because it was launched during the GLP-1 mass-market explosion. Liraglutide and exenatide are the smallest (both ~39k), reflecting their declining use.
Death reports, dulaglutide has the most at 810, followed by semaglutide (558), liraglutide (535), exenatide (511), and tirzepatide (465). Adjusted for total reports, tirzepatide and exenatide actually have the lowest death-per-1k-report rates.
Notable signals by drug:
Cleanest safety profile? On a rates-adjusted basis, tirzepatide and exenatide tie for the lowest deaths-per-1,000-reports. But adverse-event reporting is not a denominator-adjusted incidence database, higher reports reflect higher prescribing, not necessarily higher risk per patient.
Follow-up query
“For semaglutide specifically, show me the quarterly trend of psychiatric adverse events , depression, anxiety, suicidal ideation. Is there a real signal or is it reporting noise?”
Adverse-event reporting · 2018Q1–2025Q4 · 32 quarters · Comparator: liraglutide · Source: Medistill
Key inflection points
Signal vs. noise assessment
Follow-up query
“Now show me the top 50 semaglutide prescribers by plan volume, their specialties, states, and how much they receive from Novo Nordisk in industry payments. Are the highest-volume prescribers also the ones getting the most industry money?”
Plan claims (2022) · industry payments (all years) · Source: Medistill
Specialty breakdown
| Specialty | Count | Share |
|---|---|---|
| Endocrinology | 35 | 70% |
| Internal Medicine | 5 | 10% |
| Nurse Practitioner | 4 | 8% |
| Cardiology | 1 | 2% |
| Nephrology | 1 | 2% |
| Preventive Medicine | 1 | 2% |
| Family Practice | 1 | 2% |
| Physician Assistant | 1 | 2% |
| Psychiatry | 1 | 2% |
Top 15 prescribers by plan volume
| Rank | Name | Specialty | State | Plan Claims | Drug Spend | Novo Payments | Payment Type |
|---|---|---|---|---|---|---|---|
| 1 | Angueira-Serrano E | Endocrinology | FL | 2,266 | $2.4M | $130,171 | Speaker+Consult |
| 2 | Urusova I | Endocrinology | CA | 1,852 | $1.8M | $2,446 | Meals/Ed |
| 3 | Perkelvald A | Endocrinology | NY | 1,624 | $1.7M | $196,477 | Speaker |
| 4 | Cabaccan A | Endocrinology | TX | 1,393 | $1.3M | $488,063 | Speaker |
| 5 | Pittman K | Int. Medicine | SC | 1,373 | $1.5M | $488,096 | Speaker |
| 6 | Doria M | Endocrinology | NJ | 1,227 | $1.3M | $46,523 | Speaker |
| 7 | Mesquita F | Endocrinology | TX | 1,165 | $1.0M | $8,779 | Meals/Ed |
| 8 | Velez J | Endocrinology | FL | 1,107 | $1.1M | $67,422 | Speaker |
| 9 | Razzaque S | Endocrinology | TX | 1,074 | $950K | $110,553 | Speaker |
| 10 | Wang G | Endocrinology | NJ | 1,044 | $1.1M | $8,437 | Meals/Ed |
| 11 | Stein E | Endocrinology | NY | 1,031 | $1.1M | $152,729 | Speaker |
| 12 | Cohen A | Endocrinology | FL | 1,011 | $1.0M | $34,500 | Speaker |
| 13 | Shah A | Endocrinology | IL | 987 | $1.0M | $139,820 | Speaker |
| 14 | Ametov A | Endocrinology | NY | 960 | $978K | $112,854 | Speaker |
| 15 | Gonzalez-Campoy M | Endocrinology | MN | 940 | $1.1M | $232,429 | Speaker |
Correlation analysis
What you can ask
Each question runs against real data. Follow-ups build on previous results , Medistill remembers context across the entire conversation.
GLP-1 adverse event head-to-head
“Compare the complete adverse event profiles of the top 5 GLP-1 drugs, semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide. Total reports, death rate, hospitalization rate, top 10 reactions each, and demographic breakdown.”
One query across 25M+ adverse-event reports, pulls total volumes, death rates, serious outcomes, and per-drug signal breakdowns for the entire GLP-1 class.
“Show me the quarterly trend of semaglutide adverse events over the last 3 years. Are reports accelerating or stabilizing?”
Reveals whether the safety signal is growing with adoption or plateauing, critical for regulatory and commercial planning.
“For semaglutide specifically, what percentage of death outcomes involve patients over 65? Break down by sex.”
Demographic drill-down surfaces age/sex patterns that aggregate data masks, important for label updates and risk communication.
Without Medistill
Manually search adverse-event reports for each drug. No built-in comparison, no demographic breakdowns, no trend analysis. Takes days of analyst time.
KOL identification and conflict mapping
“Build me a KOL ranking for oncology. Find the top 50 oncologists by combined Medicare patient volume + PubMed publication count + industry payments + active clinical trial PI roles. Who has the highest combined influence?”
Joins four datasets in one query, Medicare utilization, PubMed, industry payments, and clinical trials, to build a multi-dimensional KOL ranking no single tool provides.
“For the top 10, show which pharma companies are paying them, what the payments are for, and which drugs they prescribe the most.”
Reveals the commercial relationship map, who’s paying your KOLs, for what, and whether their prescribing aligns.
“Are any of these KOLs running trials for a competitor while receiving payments from us? Show the potential conflicts.”
Surfaces conflict-of-interest patterns that would take weeks of manual cross-referencing across clinical-trial registry and industry payments.
Without Medistill
Requires separate subscriptions to Veeva ($200K+/yr), IQVIA, industry-payment search, PubMed, and clinical-trial registry, plus manual cross-referencing in Excel.
Drug shortage impact analysis
“Three of our products just hit the FDA drug shortage list. For each, pull the adverse-event trend before and during the shortage. Are patients switching to alternatives and experiencing more adverse events?”
Connects FDA shortage data to adverse-events in real time, shows whether shortages are causing patient harm through forced switching.
“For each shortage drug, find similar drugs by prescribing pattern. Show the safety profile of each potential substitute, which alternatives have the cleanest adverse-event record?”
Turns a reactive shortage response into a proactive substitution recommendation backed by real safety data.
Without Medistill
Check FDA shortage list manually. Separately search adverse-event reports for each drug. No way to automatically connect shortages to adverse event trends.
Psychiatric safety signal investigation
“Congress is asking about GLP-1 drugs and suicidal ideation. Pull every adverse-event report mentioning any GLP-1 drug with psychiatric adverse events, depression, anxiety, suicidal ideation, self-injury. Show by drug, by quarter, and whether reported by physician or consumer.”
Structured pharmacovigilance query across the entire GLP-1 class with reporter-type breakdown, the analysis regulators and media are already asking for.
“How does this compare to the psychiatric adverse event rate for other diabetes drugs, metformin, insulin glargine, empagliflozin? Is GLP-1 actually worse or is it proportional to prescribing volume?”
Context matters, compares GLP-1 psychiatric signals against baseline diabetes drugs to determine if the signal is class-specific or volume-driven.
“Pull the DailyMed label for semaglutide, does the current label include any psychiatric warnings or boxed warnings?”
Immediately checks whether the finding is already reflected in the label, critical for regulatory response and media inquiries.
Without Medistill
Weeks of manual adverse-event analysis. No cross-class comparison. No way to pull current drug labels in the same workflow.
Biosimilar launch targeting
“Our biosimilar is launching next quarter to compete with Humira. Show me the top 100 adalimumab prescribers by plan volume, their specialty, state, what percentage is already biosimilar vs branded, and how much they receive from AbbVie in industry payments. Who are the most likely early switchers?”
Joins prescribing data with industry payments to identify prescribers already switching to biosimilars and those with low AbbVie financial ties, your conversion targets.
“For the prescribers who are already >50% biosimilar, find 20 similar providers by utilization profile who are still on branded Humira. These are our conversion targets.”
Uses prescribing pattern similarity to find look-alike targets, providers with the same profile who haven’t switched yet.
Without Medistill
Requires IQVIA or Symphony claims data ($100K+/yr) for prescribing volumes. Industry-payment data is a separate manual search. No way to identify similar providers.
Formulary positioning analysis
“For the GLP-1 class, semaglutide, tirzepatide, liraglutide, show me which plans cover each one, what tier they’re on, and whether prior authorization or step therapy is required. How does our formulary positioning compare to competitors?”
1.12M drug-plan-tier mappings with PA and step therapy flags. See exactly where your drug sits on every plan and identify formulary gaps vs competitors.
“For plans that don’t cover tirzepatide at all, what’s their enrollment? How many beneficiaries are locked out of the newest GLP-1?”
Quantifies the patient access gap, enrollment data shows how many lives are affected by formulary exclusions.
“Map every SGLT2 inhibitor in DailyMed, brand names, RxCUI codes, pharmacologic class. Which ones share the same mechanism and which have unique labeling?”
DailyMed drug class mapping connects RxNorm codes to pharmacologic classifications, instantly shows the competitive landscape by mechanism of action.
Without Medistill
Formulary data is scattered across CMS quarterly releases. No way to query tier status, PA requirements, and enrollment in one place. Drug class mapping requires manual NLM searches.
Why switch
Adverse-event database
Adverse-event database
Subset or manual FDA search
25M+ reports, full history, all outcomes
Clinical trials
Clinical trials
clinical-trial registry manual
577K trials, searchable by drug/condition/PI/sponsor, drug×condition intersection filter returns only trials with BOTH
prescribing + formulary coverage
prescribing + formulary coverage
$100K+/yr or limited to prescribing only
All prescribers + 1.12M drug-plan-tier mappings with PA/step therapy flags
Drug labels (DailyMed)
Drug labels (DailyMed)
Manual DailyMed search
156K labels, 465K RxNorm codes, 93K pharmacologic class mappings
Industry payments (pharma $)
Industry payments (pharma $)
Separate tool
All payments, all years, joined to NPI and prescribing data
Medicaid drug utilization
Medicaid drug utilization
Not available
9.3M rows across 50 states, Medicaid drug spend and utilization by drug, state, year
Drug pricing (drug acquisition cost, ASP)
Drug pricing (drug acquisition cost, ASP)
Separate subscription
drug acquisition costs (1.6M rows) + ASP current + historical
Geographic prescriber targeting
Geographic prescriber targeting
Not available
Find prescribers within X miles by specialty, with facility affiliations
KOL identification
KOL identification
$200K+/yr (Veeva, IQVIA)
Medicare volume + PubMed + payments + trials + facility affiliations
Drug shortages
Drug shortages
Not available
Real-time FDA shortage list
Compliance screening
Compliance screening
Not available
130+ federal + state sources, FDA debarment, CLIIL, warning letters included
Any language
Any language
English only
Ask and receive answers in any language
Price
Price
$100K–$500K/yr (IQVIA, Veeva, Komodo)
From $199/mo
Data coverage
Drug Safety & Pharmacovigilance
Clinical Trials & Evidence
Prescribing & Market Intelligence
Regulatory & Approvals
25M+ adverse event reports, 577K clinical trials, 1.12M formulary mappings, 9.3M Medicaid utilization rows, 156K drug labels , all queryable through AI at from $199/month. In any language.